Neuroendocrine Cancer (@neuroendocrine) 's Twitter Profile
Neuroendocrine Cancer

@neuroendocrine

@HealthUnion Certified Patient Leader, 3 x WEGO Health (now Health Union) Award Winner, Brit/Scot, Veteran, opinions mine. Also @ronnyallan1 and @World_WNCD

ID: 3084205791

linkhttps://ronnyallan.net/ calendar_today10-03-2015 15:47:03

15,15K Tweet

5,5K Followers

2,2K Following

Pheo Para Alliance (@pheopara) 's Twitter Profile Photo

Your tireless efforts benefit so many who are affected by #NETs, including your #pheo #para #PPGL #PHriends. We appreciate that you stay on top of the literature & the latest in #neuroendocrine cancer, distill that info down & share it with your followers. ๐Ÿ™Œ๐Ÿงโค๏ธ

World Neuroendocrine Cancer Day (@world_wncd) 's Twitter Profile Photo

Neuroendocrine Neoplasms โ€“ not as rare as you think - the 10th most prevalent cancer in England. #NeuroendocrineCancer Read more on Ronny Allan #WorldNeuroendocrineCancerDay #NeuroendocrineCancer buff.ly/2MvIUYd

Neuroendocrine Neoplasms โ€“ not as rare as you think - the 10th most prevalent cancer in England. #NeuroendocrineCancer  Read more on Ronny Allan
#WorldNeuroendocrineCancerDay
 #NeuroendocrineCancer buff.ly/2MvIUYd
Ronny Allan (@ronnyallan1) 's Twitter Profile Photo

The EU approved Ipsen's (OTC: IPSEY) Cabometyx (cabozantinib) for adult patients with previously treated advanced NET, the first systemic therapy approved in the EU for this indication regardless of tumor site or grade. Cabozantinib for pNET and epNET share.google/5SPP9SbADXpEf8โ€ฆ